Skip to main content

The Administration and Study of Vaccines in Sweden

Special section on Omicron VoC: data & announcements

General information on vaccine research

Over the last two years, the COVID-19 pandemic has challenged societies and healthcare systems worldwide, and vaccines and therapeautic treatments have been rapidly developed in response. To date, the European Medicines Agency (EMA) has approved four vaccines against COVID-19:

  • Comirnaty - produced by Pfizer/BioNTech, approved on 21st December 2020.
  • Spikevax - produced by Moderna, approved on 6th January 2021.
  • Vaxzevria - produced by AstraZeneca, approved on 29th January 2021.
  • Covid-19 Vaccine - produced by Janssen, approved on 11th March 2021.
  • Nuvaxovid - produced by Novavax, approved on 20th December 2021.

As of December 2021, only Comirnaty (Pfizer/BioNTech) and Spikevax (Moderna) are available in Sweden. Vaxzevria (AstraZeneca) was used in past but is no longer used after 1st September 2021.

This page is focussed on vaccine research. On it, we visualise information about the amount of people (across different regions, different age groups, or in Sweden generally) that have received one, two, or three doses of vaccination. We also provide links to the publicly available data underlying those visualisations. The visualisations do not include information about the type of vaccine used.

The section also displays ongoing Swedish research projects related to vaccine research. These projects are focussed broadly on vaccines and, as such, they include life science projects, registery-based projects, and public health projects. We also show a subset of publications related to vaccine research by researchers affiliated with a Swedish University or Research Institute.

We invite researchers affiliated to a Swedish research institute to get in touch with us about adding information about their vaccine research data or visualisations on this page; send us an email to datacentre@scilifelab.se.

Additional resources on COVID-19 vaccines

  • The Swedish Health Agency provides general information about COVID-19 here.
  • The Swedish Medical Products Agency provides information about COVID-19 vaccines here.
  • For health information connected to vaccination and tests by different Swedish Regions, see Regional information on 1177.
  • The European Centre for Disease Prevention and Control (ECDC) shows information about the vaccines here.
  • Information about the vaccines is available from the Centre for disease Control here.
Visualisations on this page last updated: .

The visualisations in this section are based on publicly available data from the Swedish Health Agency (Folkhälsomyndigheten, FoHM). Follow this link to view their summary of statistics related to vaccination against COVID-19 in Sweden (only available in Swedish). The data used to produce the visualations can be downloaded here. For each visualisation, we describe which part of the dataset was used and how the calculations were done. The data is updated weekly (on Thursdays).

General summary statistics

In this section, we examine the overall levels of vaccination in Sweden, as well as the recent rate of vaccination.

Here, we compare two methods of calculation for the percentage of the Swedish population that has been vaccinated. One method considers only the population above 12 years of age, as only those over 12 are eligable for the vaccination. We refer to this as the ‘at least 12 years method’. The other method instead considers the number of people vaccinated as a percentage of the entire population. We refer to this as the ‘whole population method’. We display the results of both calculations for each vaccine dose (first, second, and third) on the chart below to highlight how the method of calculation used influences the measurement. Please note that the doses are sometimes referred to as first dose, fully vaccinated, and booster dose, rather than first, second and third dose.

For calculations produced using the ‘at least 12 years method’, we use data from the Vaccinerade tidsserie tab of the FoHM data, specifically the percentage calculation. For the ‘whole population method’, we instead take the total number of individuals vaccinated and use the latest count of the population size of Sweden (available from from Statistics Sweden (SCB)) to calculate it as a percentage of the population.

To summarise, in total, % of the population above around 12 years of age have received at least one dose of vaccination against COVID-19, which represents % of the whole population. The values indicate that % of the population over 12 were vaccinated over the last week (a change in rate of % compared to the previous week), or % of the whole population (a change of % compared to the previous week). By contrast, % of those over 12, and %, of the whole population have received at least two doses in total. Further, % of those over 12 and % of the whole population received their second dose last week (a change in rate of % and % compared to the previous week, respectively). Lastly, % of the population above 12 has received a third ‘booster’ dose, representing % of the whole population. Since no time series data is available for the third dose yet, it is not possible to calculate data related to rates at this stage.

Reuters COVID-19 Tracker provides some additional summary information on vaccinations against COVID-19 (as well as information regarding the implementation of lockdown measures and cases) for Sweden. In particular, the data includes how many doses would be needed to provide 100% of the population with 2 doses, and an estimation of how long (based on the current number of doses administered daily) it might take to vaccinate 10% more of the total population.

Administration of vaccinations over time

The first vaccine doses were administered in Sweden in early 2021. As with other countries, the vaccine program for the first and second doses rollout was such that the vaccine became available to decreasing age groups over time. The rollout of thirds doses is currently ongoing.

As of December 2021, data about the administration of vaccinations over time is only available for the first two doses (in the Vaccinerade tidsserie tab of FoHM data). We have presented the data for the whole of Sweden as a percentage of the Swedish population in the below graph (using the latest population size data from Statistics Sweden (SCB)). In future we hope to also be able to show data for the third dose.

Please keep in mind that this data differs from the percentages as calculated by FoHM, who use the ‘at least 12 years method’. However, the data is comparable to the calculations reported by other countries, see the information in the ‘general summary statistics’ section for details.

Note on the graph: Click on the coloured squares in the legend of the below graph to toggle which datasets are displayed.

Administration of vaccinations in each county (län)

In this section, we explore the levels of vaccination coverage for each of the three doses in each county (län) of Sweden. We again use the latest data on the population size for each county from Statistics Sweden (SCB) to calculate the coverage for each dose as a percentage of the whole population of that county. We take the number of first and second doses administered in that county from the ‘Vaccinerade tidsserie’ tab of the data from FoHM. Again, please note that the ‘raw numbers’ related to these doses represent the vaccinations administered to those aged at least 12. As of December 2021, there is no directly comparable ‘raw numbers’ data available for the third ‘booster’ dose. However, data is available on the total number of individuals aged 18+ that have received each dose in each county (see ‘Totalt’ values in the Dos 3 per åldersgrupp tab of the data from FoHM). We have therefore made use of these values to calculate the percentage of the population that have received the third dose.

Again, please note that these percentage values will differ from those calculated by FoHM, whose calculations do not consider the whole population, but rather the population born since 2009 (i.e. those above 12 years of age).

Administration of one vaccine dose

Administration of two vaccine doses

Administration of three vaccine doses

Administration of vaccinations according to age group

We constructed the below heatmap to show how the relative numbers of people vaccinated differs according to age. Unsurprisingly, the more advanced age groups tend to have higher levels of vaccination for each dose, as they are given access at an earlier stage.

As of December 2021, data is available for individuals above the age of 12 for the first and second vaccine doeses (available in the ‘Vaccinerade ålder’ tab of the data from FoHM), and for people above the age of 18 for the third dose (available in the ‘Dos 3 per åldersgrupp’ tab of the data from FoHM). In this case, we have not performed any recalculation, so the numbers are the same as those provided by FoHM.

Note about the heatmap: A white colouration indicates that no data is available for that age group.

Ongoing research projects

Below is a manually curated overview of projects focussed on vaccine research that are/were funded by major funding agencies in Sweden. As it is manually curated, the list may not be exhaustive, but new projects will be added as soon as possible. If you are aware of a project that is not listed here but ought to be, please get in touch with us. For a list of all research projects funded by major funding agencies in Sweden, see this section of the portal instead.

Project title Principal investigator PI affiliation Funder Duration
The immunology of adverse events to SARS-CoV-2 vaccines Petter Brodin Karolinska Institute SciLifeLab / Knut and Alice Wallenberg Foundation 2021 - 2022
Register-based large-scale national population study to monitor Covid-19 vaccination effectiveness and safety (RECOVAC) Fredrik Nyberg University of Gothenburg SciLifeLab / Knut and Alice Wallenberg Foundation 2021 - 2022
The Stockholm 65PLUS cohort- A prospective longitudinal study of immune responses induced after Covid-19 vaccination Anna-Lena Spetz Stockholm University SciLifeLab / Knut and Alice Wallenberg Foundation 2021 - 2022
Impact of immune suppressants on SARS-CoV 2 vaccination responses Fredrik Piehl Karolinska Institute SciLifeLab / Knut and Alice Wallenberg Foundation 2021 - 2022
SARS-CoV-2 infections in relation to vaccination among healthcare workers of the Stockholm Region Joakim Dillner Karolinska Institute SciLifeLab / Knut and Alice Wallenberg Foundation 2021 - 2022
Immune responses to COVID-19 vaccination in unexposed, previously infected and immunosuppressed individuals Anna Lundgren University of Gothenburg SciLifeLab / Knut and Alice Wallenberg Foundation 2021 - 2022
CoVASC - Covid Vaccination Antibody structural correlates Johan Malmström Lund University SciLifeLab / Knut and Alice Wallenberg Foundation 2021 - 2022
Covid-19 vaccination in immunocompromised individuals: An interdisciplinary framework to gain mechanistic insight into durable immunity to SARS-CoV-2 infection Soo Aleman Karolinska Institute SciLifeLab / Knut and Alice Wallenberg Foundation 2021 - 2022
Efficacy and immunogenicity of a SARS-CoV-2 vaccine in highly immunocompromised recipients of CAR T cell therapy and allogeneic stem cell transplantation Karin Loré Karolinska Institute SciLifeLab / Knut and Alice Wallenberg Foundation 2021 - 2022
High Resolution Analysis of Vaccine-Induced Responses in SARS-CoV-2 Experienced Individuals Mattias Forsell Umeå University SciLifeLab / Knut and Alice Wallenberg Foundation 2021 - 2022
Antibody specificities for protective immunity after Covid-19 vaccination Karin Loré Karolinska Institute Swedish Research Council 2020-08-01 - 2020-12-31
Design and development of mucosal vaccine vectors in commensal bacteria expressing SARS-CoV-2 antigens as a potential prophylactic method Lars Engstrand Karolinska Institute Swedish Research Council 2020-12-01 - 2021-12-31
Rapid therapy development through Open Coronavirus Vaccine Platform Matti Sällberg, Gustaf Ahlén Karolinska Institute Horizon 2020 2020-04-01 - 2022-03-31
Studie av 'mördar' celler inför vaccinutveckling Kristian Riesbeck Skåne University Hospital Malmö Hjärt-Lungfonden -
Vaccin mot SARS-CoV-2 Jan Lötvall Sahlgrenska University Hospital Hjärt-Lungfonden -
COVID-19 Vaccine Effect, Response and Safety (COVERS) Sweden: Clinical and epidemiological studies with particular focus on vulnerable groups Clas Ahlm Umeå University Swedish Research Council -
Register studies and immunological effect studies of COVID-19 vaccination and build-up of infrastructure for pandemic preparedness at national level (RE-VISION) Magnus Gisslén University of Gothenburg Swedish Research Council -
FASTER – National COVID-19 vaccine research platform Pontus Naucler Karolinska Institute Swedish Research Council -
Real time evaluation of COVID-19 vaccination in Swedish healthcare regions based on an information platform that supports system modelling and machine learning Thomas Schön Linköping University Swedish Research Council -
Epidemiological, immunological and genetic mapping of side effects of COVID-19 vaccines Mia Wadelius Uppsala University Swedish Research Council -
Ryktesspridning och tillit bland vaccinskeptiska grupper i Sverige Sibylle Herzig van Wees Karolinska Institute Forte 2022 - 2023
Rollen för MAIT celler i COVID-19 immunpatogenes och mRNA vaccin responsen Johan Sanberg Karolinska Institutet Swedish Research Council 2021 - 2023

Publications

Below is a subset of preprints and published scientific journal articles on the subject of vaccine research involving at least one author affiliated with a Swedish university or research institute. If you would like for your publication to be displayed here, or feel that information about a publication requires correction, please get in touch with us. For a full list of all publications related to COVID-19 and SARS-CoV-2 that involve at least one author affiliated with a Swedish university or research institute, please see this section of the portal.

Publication Published
Disease severity related to VOC dominance in unvaccinated SARS-CoV-2 positive adults without risk factors in Sweden
Wahlström E, Bruce D, Bennet Bark AM, Walther S, Hanberger H, Strålin K
. DOI: 10.1101/2021.12.23.21268040 preprint
2021-12-27
Brand-Specific Enhanced Safety Surveillance Study of GSK's Quadrivalent Seasonal Influenza Vaccine, Conducted During the COVID-19 Pandemic, in Belgium, Germany and Spain, for the 2020/21 Season.
Dos Santos G, Wang H, Jindal P, Rybo M, Roul H, Pallem S, Eckermann T, Godderis L, Martínez Gómez X, Godard E, Soler M, Yousefi M, Salamanca de la Cueva I, Nwoji U
Infect Dis Ther. DOI: 10.1007/s40121-021-00571-y
2021-12-27
Differential Effect of SARS-CoV-2 Spike Glycoprotein 1 on Human Bronchial and Alveolar Lung Mucosa Models: Implications for Pathogenicity.
Rahman M, Irmler M, Keshavan S, Introna M, Beckers J, Palmberg L, Johanson G, Ganguly K, Upadhyay S
Viruses 13 (12). DOI: 10.3390/v13122537 data available
2021-12-17
Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination
Kaku CI, Champney ER, Normark J, Johnson CE, Ahlm C, Sakharkar M, Ackerman ME, Forsell MNE, Walker LM
. DOI: 10.1101/2021.12.13.21267598 preprint
2021-12-14
The profile of the COvid-19 VACcination register SAFEty study in Sweden (CoVacSafe-SE).
Ljung R, Sundström A, Grünewald M, Backman C, Feltelius N, Gedeborg R, Zethelius B
Ups J Med Sci 126. DOI: 10.48101/ujms.v126.8136
2021-12-10
Increasing risk of breakthrough COVID-19 in outbreaks with high attack rates in European long-term care facilities, July to October 2021
Suetens C, Kinross P, Gallego Berciano P, Arroyo Nebreda V, Hassan E, Calba C, Fernandes E, Peralta-Santos A, Casaca P, Shodu N, Dequeker S, Kontopidou F, Pappa L, Kacelnik O, Børseth AW, O’Connor L, Garvey P, Liausedienė R, Valintelienė R, Ernst C, Mossong J, Štefkovičová M, Prostináková Z, Danielsen AC, Mougkou A, Lamb F, Cenciarelli O, Monnet DL, Plachouras D
Euro Surveill 26 (49). DOI: 10.2807/1560-7917.es.2021.26.49.2101070
2021-12-09
To be or not to be vaccinated against COVID-19 - The adolescents' perspective - A mixed-methods study in Sweden.
Nilsson S, Mattson J, Berghammer M, Brorsson AL, Forsner M, Jenholt Nolbris M, Kull I, Lindholm Olinder A, Ragnarsson S, Rullander AC, Rydström LL, Andréia Garcia de Avila M, Olaya-Contreras P
Vaccine X 9 100117. DOI: 10.1016/j.jvacx.2021.100117
2021-12-00
A population-based dataset concerning predictors of willingness to get a COVID-19 vaccine in Iran.
Pakpour AH, Yahaghi R, Ahmadizade S, Fotuhi R, Taherkhani E, Ranjbaran M, Buchali Z, Lin C, Griffiths MD, Broström A
Data Brief 39 107459. DOI: 10.1016/j.dib.2021.107459
2021-12-00
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, Chen P, Söderdahl G, Österborg A, Smith CIE, Wullimann D, Vesterbacka J, Lindgren G, Blixt L, Friman G, Wahren-Borgström E, Nordlander A, Gomez AC, Akber M, Valentini D, Norlin AC, Thalme A, Bogdanovic G, Muschiol S, Nilsson P, Hober S, Loré K, Chen MS, Buggert M, Ljunggren HG, Ljungman P, Aleman S, COVAXID-collaborator group (shown separately)
EBioMedicine 74 103705. DOI: 10.1016/j.ebiom.2021.103705
2021-11-29
Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination.
Cagigi A, Yu M, Österberg B, Svensson J, Falck-Jones S, Vangeti S, Åhlberg E, Azizmohammadi L, Warnqvist A, Falck-Jones R, Gubisch PC, Ödemis M, Ghafoor F, Eisele M, Lenart K, Bell M, Johansson N, Albert J, Sälde J, Pettie DD, Murphy MP, Carter L, King NP, Ols S, Normark J, Ahlm C, Forsell MN, Färnert A, Loré K, Smed-Sörensen A
JCI Insight 6 (22). DOI: 10.1172/jci.insight.151463
2021-11-22
COVID-19 vaccination in autoimmune disease (COVAD) survey protocol.
Sen P, Gupta L, Lilleker JB, Aggarwal V, Kardes S, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, O'Callaghan AS, Nikiphorou E, Tan AL, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Cagnotto G, Nune A, Distler O, Chinoy H, Aggarwal V, Aggarwal R, COVAD Study Group
Rheumatol Int. DOI: 10.1007/s00296-021-05046-4
2021-11-15
Utilization of health care services before and after media attention about fatal side effects of the AstraZeneca vaccine: a nation-wide register-based event study.
Larsen VB, Grøsland M, Telle K, Magnusson K
BMC Health Serv Res 21 (1) 1229. DOI: 10.1186/s12913-021-07233-2
2021-11-13
Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy.
Lockmer S, Uttervall K, Kashif M, Svärd C, Malmsten K, Fletcher-Torres E, Alici E, Lund J, Nahi H
Am J Hematol 96 (11) E443-E446. DOI: 10.1002/ajh.26348
2021-11-01
Allergen Immunotherapy management during vaccinations: An international survey.
Masieri S, Bachert C, Ojeda P, Kim CK, Carlo C, Giorgio C, Study Group on AIT & Vaccinations
World Allergy Organ J 14 (11) 100601. DOI: 10.1016/j.waojou.2021.100601
2021-11-00
Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database.
Kim MS, Jung SY, Ahn JG, Park SJ, Shoenfeld Y, Kronbichler A, Koyanagi A, Dragioti E, Tizaoui K, Hong SH, Jacob L, Salem JE, Yon DK, Lee SW, Ogino S, Kim H, Kim JH, Excler JL, Marks F, Clemens JD, Eisenhut M, Barnett Y, Butler L, Ilie CP, Shin EC, Il Shin J, Smith L
J Med Virol. DOI: 10.1002/jmv.27424
2021-10-28
Susceptibility of Dog, Hamster, and Mouse Cells to the Replication-Competent Adenovirus 11p E1/E3 Green Fluorescence Protein Vector Has Implications for the Selection of Animal Vaccine Models.
Gokumakulapalle M, Wang L, Mei YF
Front Microbiol 12 698999. DOI: 10.3389/fmicb.2021.698999
2021-10-27
Structural Modeling on the Determinants of Effectiveness of SOPs Containing COVID-19 in Mass Gatherings.
Basit A, Scholz M, Niazi AAK, Qazi TF, Shaukat MZ, Rao ZU, Mahmood A
Front Psychol 12 755221. DOI: 10.3389/fpsyg.2021.755221
2021-10-27
GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults
Lanini S, Capone S, Antinori A, Milleri S, Nicastri E, Camerini R, Agrati C, Castilletti C, Mori F, Sacchi A, Matusali G, Gagliardini R, Ammendola V, Cimini E, Grazioli F, Scorzolini L, Napolitano F, Plazzi MM, Soriani M, De Luca A, Battella S, Sommella A, Contino AM, Barra F, Gentile M, Raggioli A, Shi Y, Girardi E, Maeurer M, Capobianchi MR, Vaia F, Piacentini M, Kroemer G, Vitelli A, Colloca S, Folgori A, Ippolito G, Ottou S, Vita S, Vergori A, D’Abramo A, Petrecchia A, Montaldo C, Scalise E, Grassi G, Casetti R, Bordoni V, Notari S, Colavita F, Meschi S, Lapa D, Bordi L, Murachelli S, Tambasco T, Grillo A, Masone E, Marchioni E, Bardhi D, Porzio O, Cocca F, Murachelli S, Turrini I, Malescio F, Ziviani L, Lawlor R, Poli F, Martire F, Zamboni D, Mazzaferri F
Sci. Transl. Med.. DOI: 10.1126/scitranslmed.abj1996
2021-10-26
Lack of Trust, Insufficient knowledge and Risk denial; an in-depth Understanding of Health workers Barriers to uptake of the Covid-19 vaccine at Iganga Hospital Eastern Uganda, and Mengo Hospital Kampala Uganda
Muhamadi L, Edith N, James W, Tumwesigye NM, Museene SK, Mukakaarisa H, Peterson SS, Ekström AM
. DOI: 10.1101/2021.10.13.21264920 preprint
2021-10-19
Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time
Havervall S, Marking U, Greilert-Norin N, Gordon M, Ng H, Christ W, Phillipson M, Nilsson P, Hober S, Blom K, Klingström J, Mangsbo S, Åberg M, Thålin C
. DOI: 10.1101/2021.10.16.21264948 preprint
2021-10-19
Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients.
Melin J, Svensson MK, Albinsson B, Winqvist O, Pauksens K
BMC Immunol 22 (1) 70. DOI: 10.1186/s12865-021-00458-0
2021-10-19
Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination.
Cagigi A, Yu M, Österberg B, Svensson J, Falck-Jones S, Vangeti S, Åhlberg E, Azizmohammadi L, Warnqvist A, Falck-Jones R, Gubisch PC, Ödemis M, Ghafoor F, Eisele M, Lenart K, Bell M, Johansson N, Albert J, Sälde J, Pettie DD, Murphy MP, Carter L, King NP, Ols S, Normark J, Ahlm C, Forsell MN, Färnert A, Loré K, Smed-Sörensen A
JCI Insight. DOI: 10.1172/jci.insight.151463
2021-10-19
Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study.
Nordström P, Ballin M, Nordström A
Lancet Reg Health Eur 100249. DOI: 10.1016/j.lanepe.2021.100249
2021-10-18
Adverse events of special interest for COVID-19 vaccines - background incidences vary by sex, age and time period and are affected by the pandemic
Nyberg F, Lindh M, Vanfleteren LEGW, Hammar N, Wettermark B, Sundström J, Santosa A, Kirui BK, Gisslén M
. DOI: 10.1101/2021.10.04.21263507 preprint
2021-10-05
High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population – first results from a cohort study in Southern Sweden
Björk J, Inghammar M, Moghaddassi M, Rasmussen M, Malmqvist U, Kahn F
Infect Dis (Lond) 1-6. DOI: 10.1080/23744235.2021.1982144
2021-09-29
Identification of Unique Peptides for SARS-CoV-2 Diagnostics and Vaccine Development by an In Silico Proteomics Approach
Kesarwani V, Gupta R, Vetukuri RR, Kushwaha SK, Gandhi S
Front Immunol 12. DOI: 10.3389/fimmu.2021.725240
2021-09-24
Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARS-CoV-2 vaccination.
van de Munckhof A, Krzywicka K, Aguiar de Sousa D, Sánchez van Kammen M, Heldner MR, Jood K, Lindgren E, Tatlisumak T, Putaala J, Kremer Hovinga JA, Middeldorp S, Levi M, Arnold M, Ferro JM, Coutinho JM
Eur J Neurol. DOI: 10.1111/ene.15113
2021-09-18
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, Chen P, Söderdahl G, Österborg A, Edvard Smith CI, Wullimann D, Vesterbacka J, Lindgren G, Blixt L, Friman G, Wahren-Borgström E, Nordlander A, Gomez AC, Akber M, Valentini D, Norlin AC, Thalme A, Bogdanovic G, Muschiol S, Nilsson P, Hober S, Loré K, Chen MS, Buggert M, Ljunggren HG, Ljungman P, Aleman S, None
. DOI: 10.1101/2021.09.07.21263206 preprint
2021-09-12
Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination.
Normark J, Vikström L, Gwon Y, Persson I, Edin A, Björsell T, Dernstedt A, Christ W, Tevell S, Evander M, Klingström J, Ahlm C, Forsell M
N Engl J Med 385 (11) 1049-1051. DOI: 10.1056/NEJMc2110716
2021-09-09
Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021.
Seppälä E, Veneti L, Starrfelt J, Danielsen AS, Bragstad K, Hungnes O, Taxt AM, Watle SV, Meijerink H
Euro Surveill 26 (35). DOI: 10.2807/1560-7917.ES.2021.26.35.2100793
2021-09-00
COVID-19 vaccine uptake among older people in relation to sociodemographic factors –cohort results from southern Sweden
Inghammar M, Moghaddassi M, Rasmussen M, Malmqvist U, Kahn F, Björk J
. DOI: 10.1101/2021.08.12.21261981 preprint
2021-08-13
Neutralization of VOCs including Delta one year post COVID-19 or vaccine
Havervall S, Marking U, Gordon M, Ng H, Greilert-Norin N, Lindbo S, Blom K, Nilsson P, Phillipson M, Klingström J, Mangsbo S, Åberg M, Hober S, Thålin C
MedRxiv. DOI: 10.1101/2021.08.12.21261951 preprint
2021-08-12
Initial impact of SARS-Cov-2 vaccination on healthcare workers in Italy- Update on the 28th of March 2021.
Mateo-Urdiales A, Del Manso M, Andrianou X, Spuri M, D'Ancona F, Filia A, Rota MC, Petrone D, Vescio MF, Riccardo F, Bella A, Pezzotti P, Fabiani M
Vaccine 39 (34) 4788-4792. DOI: 10.1016/j.vaccine.2021.07.003
2021-08-09
Swedish Covid-19 Investigation for Future Insights - A Population Epidemiology Approach Using Register Linkage (SCIFI-PEARL).
Nyberg F, Franzén S, Lindh M, Vanfleteren L, Hammar N, Wettermark B, Sundström J, Santosa A, Björck S, Gisslén M
CLEP 13 649-659. DOI: 10.2147/CLEP.S312742
2021-07-30
Vaccine allergy: evidence to consider for COVID-19 vaccines.
Nilsson L, Csuth Á, Storsaeter J, Garvey LH, Jenmalm MC
Curr Opin Allergy Clin Immunol. DOI: 10.1097/ACI.0000000000000762
2021-06-04
DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice
Szurgot I, Hanke L, Sheward DJ, Vidakovics LP, Murrell B, McInerney GM, Liljeström P
Sci Rep 11 (1) 3125. DOI: 10.1038/s41598-021-82498-5
2021-02-04
SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
Tian JH, Patel N, Haupt R, Zhou H, Weston S, Hammond H, Logue J, Portnoff AD, Norton J, Guebre-Xabier M, Zhou B, Jacobson K, Maciejewski S, Khatoon R, Wisniewska M, Moffitt W, Kluepfel-Stahl S, Ekechukwu B, Papin J, Boddapati S, Jason Wong C, Piedra PA, Frieman MB, Massare MJ, Fries L, Bengtsson KL, Stertman L, Ellingsworth L, Glenn G, Smith G
Nat Commun 12 (1) 372. DOI: 10.1038/s41467-020-20653-8 data available
2021-01-14